Retatrutide is a next-generation triple agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously
Musculoskeletal and Connective Tissue Models Tendon, ligament, and muscle repair models represent a major area of TB-500 lab research interest
Tirzepatides multifaceted approach to blood sugar control and weight management makes it an effective treatment for metabolic syndrome, a cluster of conditions that increase the risk of heart disease, stroke, and diabetes
Obesity itself can lead to depression and anxiety, which can sometimes lead to suicidal thoughts and actions
Use for non-HIV indications including off-label use for general visceral fat reduction, metabolic syndrome, or body composition is not FDA-approved and is considered off-label or research use